News

In connection with the clearance, Schering-Plough has agreed to divest certain animal health products in Europe. The divestitures are not material to the company’s financial results. No divestitures

The study, known as the Choice trial, is evaluating the efficacy and safety of daclizumab or placebo added to interferon beta therapy in 230 patients with active multiple

The clinical trial utilized a two stage design to ensure there would be an adequate response rate to justify complete enrollment. Tumor response was evaluated at baseline and

Sofgen will be responsible for development and manufacturing of the product. Akorn will be responsible for the regulatory submission, marketing and distribution in the US and Puerto Rico.

Ralph Makar, the newly appointed president and CEO of Bioject, said: “We are pleased to enter into this new agreement with Merck Serono, which is the continuation of

This agreement provides Sirtris with exclusive rights to intellectual property covered under the patent ‘cholesterol-regulating complex of SIRT1 and LXR and methods of use.’ Karl Normington, Sirtris’ senior

Under the terms of the offering, CombinatoRx will sell 5.6 million shares of its common stock at a price of $6.25 per share, which represents a 6.5% discount

This study will enroll approximately 56 evaluable patients. The primary efficacy objective is the response rate (confirmed complete response or confirmed complete response without platelet recovery) achieved over

The payment is in the form of equity securities in iCo Therapeutics. The licensed drug designed and discovered by Isis, iCo-007, is a second-generation antisense drug that inhibits